ImExHS Limited (ASX:IME)
Australia · Delayed Price · Currency is AUD | Market Cap | 20.55M +0.1% |
| Revenue (ttm) | 28.97M +9.2% |
| Net Income | -2.88M |
| EPS | -0.06 |
| Shares Out | 54.07M |
| PE Ratio | n/a |
| Forward PE | 18.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,983 |
| Average Volume | 35,876 |
| Open | 0.3850 |
| Previous Close | 0.3850 |
| Day's Range | 0.3800 - 0.3850 |
| 52-Week Range | 0.2200 - 0.4700 |
| Beta | 0.83 |
| RSI | 46.02 |
| Earnings Date | Feb 26, 2026 |
About ImExHS
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. The company operates in two segments: Software and Radiology. It offers medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company’s solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; and ANTEROS, a cardiology software solution.... [Read more]
Financial Performance
In 2025, ImExHS's revenue was 28.97 million, an increase of 9.17% compared to the previous year's 26.54 million. Losses were -2.88 million, 9.78% more than in 2024.
Financial StatementsNews
ImExHS Earnings Call Transcript: H2 2025
Revenue rose 10% to AUD 29 million and underlying EBITDA more than tripled to AUD 1.6 million, driven by strong ARR growth and operational improvements. FY 2026 guidance targets further EBITDA gains, cash positivity, and accelerated software revenue, with growth weighted to H2.
ImExHS Earnings Call Transcript: Q3 2025
Q3 marked a financial turning point with ARR up 24% year-over-year and positive cash flow. AQUILA+ software and disciplined cost management drove margin gains, while new pricing segmentation and partner channels strengthened the pipeline. Guidance for FY revenue and EBITDA was reaffirmed.
ImExHS Earnings Call Transcript: H1 2025
Aquila Plus drove ARR growth with new wins in Colombia and Mexico, while revenue rose 4% year-on-year to $13.7 million and ARR reached $32.8 million, up 11%. FY2025 guidance projects revenue of $27.5–$28.2 million and EBITDA of $1.3–$1.6 million.
ImExHS Earnings Call Transcript: H2 2024
Revenue grew 34% year-on-year to AUD 26.5 million, with 97% recurring and ARR up 20%. Software and radiology services segments both saw double-digit growth, while disciplined cost control and new contracts supported margin improvements.
ImExHS Earnings Call Transcript: H1 2024
Revenue grew 57% year-on-year to AUD 13.8 million, with ARR up 21% and recurring revenue at 95% of total. Margin improvement, price increases, and upselling are key focuses for the second half, with FY 2024 revenue forecasted at AUD 24–27 million.